Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 8, 2013, Pages

  Gao, Yang ^a   Romero Aleshire, Melissa J ^a   Cai, Qi ^a   Price, Theodore J ^a   Brooks, Heddwen L ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Aquaporin 2; Collecting ducts; GSK3 ; Urea transporter

Indexed keywords

AQUAPORIN 2; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; INITIATION FACTOR 4E BINDING PROTEIN; LITHIUM; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROSTAGLANDIN SYNTHASE; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; KIDNEY CELL; KIDNEY COLLECTING DUCT CELL; KIDNEY COLLECTING TUBULE; KIDNEY CYST; KIDNEY FUNCTION; KIDNEY MEDULLA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; URINALYSIS; URINE OSMOLALITY;

EID: 84885604333     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00153.2013     Document Type: Article

References (41)

1. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, Wang S, Weinstein IB, Holt PR. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110: 669-674, 1996.
2. Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, Walker RJ. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol 3: 1324-1331, 2008.
3. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 10: 329-345, 1987.
4. Brooks HL, Sorensen AM, Terris J, Schultheis PJ, Lorenz JN, Shull GE, Knepper MA. Profiling of renal tubule Na transporter abundances in NHE3 and NCC/TSC null mice using targeted proteomics. J Physiol 530: 359-366, 2001.
5. Brooks HL, Ageloff S, Kwon TH, Brandt W, Terris JM, Seth A, Michea L, Nielsen S, Fenton R, Knepper MA. cDNA array identification of genes regulated in rat renal medulla in response to vasopressin infusion. Am J Physiol Renal Physiol 284: F218-F228, 2003.
6. Cai Q, McReynolds MR, Keck M, Greer KA, Hoying JB, Brooks HL. Vasopressin receptor subtype 2 activation increases cell proliferation in the renal medulla of AQP1 null mice. Am J Physiol Renal Physiol 293: F1858-F1864, 2007.
7. Christensen BM, Kim YH, Kwon TH, Nielsen S. Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol 291: F39-F48, 2006.
8. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11: 957-972, 1997.
9. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328: 1172-1176, 2010.
10. Farres MT, Ronco P, Saadoun D, Remy P, Vincent F, Khalil A, Le Blanche AF. Chronic lithium nephropathy: MR imaging for diagnosis. Radiology 229: 570-574, 2003.
11. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38, 2009.
12. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216, 2004.
13. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12: 502-513, 1998.
14. Golshayan D, Nseir G, Venetz JP, Pascual M, Barbey F. MR imaging as a specific diagnostic tool for bilateral microcysts in chronic lithium nephropathy. Kidney Int 81: 601, 2012.
15. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
16. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
17. Kishore BK, Ecelbarger CM. "Lithium" a versatile tool to understand renal physiology. Am J Physiol Renal Physiol 304: F1139-F1149, 2013.
18. Kjaersgaard G, Madsen K, Marcussen N, Christensen S, Walter S, Jensen BL. Tissue injury after lithium treatment in human and rat postnatal kidney involves glycogen synthase kinase-3 beta-positive epithelium. Am J Physiol Renal Physiol 302: F455-F465, 2012.
19. Klein JD, Gunn RB, Roberts BR, Sands JM. Downregulation of urea transporters in the renal inner medulla of lithium-fed rats. Kidney Int 61: 995-1002, 2002.
20. Kojima N, Saito H, Nishikawa M, Yuri S, Jo OD, Pham PC, Yanagawa N, Yanagawa N. Lithium induces c-Ret expression in mouse inner medullary collecting duct cells. Cell Signal 23: 371-379, 2011.
21. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339-345, 2003.
22. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441: 1-21, 2012.
23. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10: 151-162, 2002.
24. McReynolds MR, Taylor-Garcia KM, Greer KA, Hoying JB, Brooks HL. Renal medullary gene expression in aquaporin-1 null mice. Am J Physiol Renal Physiol 288: F315-F321, 2005.
25. Nielsen J, Hoffert JD, Knepper MA, Agre P, Nielsen S, Fenton RA. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. Proc Natl Acad Sci USA 105: 3634-3639, 2008.
26. Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence JC Jr, Sonenberg N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5=-cap function. Nature 371: 762-767, 1994.
27. Rao R, Zhang MZ, Zhao M, Cai H, Harris RC, Breyer MD, Hao CM. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol 288: F642-F649, 2005.
28. Rojek A, Nielsen J, Brooks HL, Gong H, Kim YH, Kwon TH, Frokiaer J, Nielsen S. Altered expression of selected genes in kidney of rats with lithium-induced NDI. Am J Physiol Renal Physiol 288: F1276-F1289, 2005.
29. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 6: 304-312, 2007.
30. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, Cook LJ, Rubinsztein DC. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 170: 1101-1111, 2005.
31. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17: 170-178, 2008.
32. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103: 5466-5471, 2006.
33. Shillingford JM, Piontek KB, Germino GG, Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21: 489-497, 2010.
34. Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, Bruno F, Montemurno E, Schirinzi A, Sabbatini M, Pisani A, Tataranni T, Schena FP, Gesualdo L. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYDstudy): a randomized, controlled study. Nephrol Dial Transplant 27: 3560-3567, 2012.
35. Sugawara M, Hashimoto K, Ota Z. Involvement of prostaglandin E2, cAMP, and vasopressin in lithium-induced polyuria. Am J Physiol Regul Integr Comp Physiol 254: R863-R869, 1988.
36. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032, 2009.
37. Timmer RT, Sands JM. Lithium intoxication. J Am Soc Nephrol 10: 666-674, 1999.
38. Wahl PR, Serra AL, Le HM, Molle KD, Hall MN, Wuthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006.
39. Walker RG. Lithium nephrotoxicity. Kidney Int Suppl 42: S93-S98, 1993.
40. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940, 2007.
41. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.